Verrica Pharmaceuticals Set to Release Q4 2025 Earnings on March 10

Verrica Pharmaceuticals (NASDAQ: VRCA) is scheduled to announce its Q4 2025 earnings on Tuesday, March 10, 2026, before the market opens. Analysts predict that the company will report a loss of ($0.43) per share alongside revenues of $4.52 million for the quarter. Investors and stakeholders can access further details on the earnings call, which is set for 5:00 PM ET on March 13, 2026.

Shares of Verrica Pharmaceuticals opened at $5.37 on Tuesday, reflecting a market capitalization of $85.87 million. The company’s price-to-earnings (P/E) ratio stands at -1.57, indicating a challenging period for profitability. The stock has experienced volatility, with a fifty-day moving average of $7.13 and a two-hundred-day moving average of $5.88. Over the past year, the shares have fluctuated between a low of $3.28 and a high of $9.82.

Analysts React with Mixed Ratings

Recent reports from various equities research analysts have highlighted differing perspectives on Verrica Pharmaceuticals’ stock. On January 7, TD Cowen reaffirmed a “buy” rating for the company. Meanwhile, Brookline Capital Acquisition upgraded its rating from “hold” to “buy” with a price target of $17.00 on December 18. Loop Capital also set a price objective of $17.00 on the same day.

Conversely, Wall Street Zen downgraded the stock from “buy” to “hold” as of February 7. Despite these mixed reviews, Zacks Research has upgraded Verrica Pharmaceuticals from “hold” to “strong-buy” as of January 9. Overall, the stock has received one Strong Buy rating, two Buy ratings, two Hold ratings, and one Sell rating, resulting in a consensus rating of “Moderate Buy” and a consensus price target of $17.00, according to MarketBeat.com.

Institutional Investors Increase Stake

Institutional investors and hedge funds have recently adjusted their holdings in Verrica Pharmaceuticals, indicating growing interest in the company. Bank of America Corp DE significantly increased its position by 347.5% in the fourth quarter, now owning 143,818 shares valued at approximately $101,000 after acquiring an additional 111,678 shares.

Similarly, Invesco Ltd. boosted its stake by 64.8% in the first quarter, bringing its total to 74,388 shares worth $33,000. AQR Capital Management LLC increased its stake by 306.7%, now holding 58,711 shares valued at $26,000. Goldman Sachs Group Inc. also raised its position by 23.3%, owning 139,055 shares valued at $61,000.

Hedge funds and institutional investors collectively own 42.45% of Verrica Pharmaceuticals’ stock, suggesting a significant level of confidence in the company’s future prospects.

Verrica Pharmaceuticals, based in the United States, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin designed to treat molluscum contagiosum and common warts. The company emphasizes patient convenience and dosing consistency, differentiating its approach from off-label treatments.

Additionally, Verrica is advancing VP-103, a next-generation topical candidate aimed at optimizing tolerability while maintaining efficacy against viral skin lesions. As the earnings report approaches, investors and analysts alike will be closely monitoring the outcomes and future guidance from Verrica Pharmaceuticals.